Investigational drug · Phase 3
allo-APZ2-CVU
Also called: Skin-derived ABCB5-positive dermal mesenchymal stromal cells
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Venous Leg Ulcer, Skin Ulcer Venous Stasis Chronic.
Phase 3Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "allo-APZ2-CVU"
First trial start
2021
Aug 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "allo-APZ2-CVU", any sponsor or status.
Conditions studied
As listed on its trial records.
- Venous Leg Ulcer
- Skin Ulcer Venous Stasis Chronic
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "allo-APZ2-CVU" as an intervention, largest first.
- Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)Pivotal-lookingActive, not recruiting
RHEACELL GmbH & Co. KGIndustry
NCT06489028 · 250 participants (planned) · Start Dec 26, 2024 · Primary completion Apr 2027
Drug: allo-APZ2-CVU; Placebo · For: Venous Leg Ulcer
Sites: Hialeah, Florida; Miami, Florida; Boston, Massachusetts · 15 sites in all
- Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)Pivotal-lookingCompleted
RHEACELL GmbH & Co. KGIndustry
NCT04971161 · 159 participants · Start Aug 18, 2021 · Primary completion Nov 25, 2025
Drug: allo-APZ2-CVU; Placebo · For: Skin Ulcer Venous Stasis Chronic
Sites: Aachen, Germany; Augsburg, Germany; Bad Bentheim, Germany · 38 sites in all
RHEACELL GmbH & Co. KGIndustry
NCT03257098 · 31 participants · Start Nov 16, 2017 · Primary completion Jun 25, 2020
Drug: allo-APZ2-CVU · For: Skin Ulcer Venous Stasis Chronic
Sites: Bochum, Germany; Erlangen, Germany; Greifswald, Germany · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Venous Leg Ulcer
- TR987 0.1%Phase 32 trials
TR Therapeutics · Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer
- MTX-001human amniotic fluidPhase 21 trial
Merakris Therapeutics · Venous Stasis Ulcer, Venous Leg Ulcer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.